Gilead Sciences Overview
- Founded
- 1987
- Status
- Public
- Employees
- 11,800
- Stock Symbol
- GILD
- Investments
- 47
- Share Price
- $59.89
- (As of Monday Closing)
Gilead Sciences General Information
Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Contact Information
Website
Formerly Known As
Oligogen
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
- 333 Lakeside Drive
- Foster City, CA 94404
- United States
+1 (650) 000-0000
Gilead Sciences Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $59.89 | $60.11 | $57.04 - $85.97 | $75.3B | 1.25B | 9.4M | $0.99 |
Gilead Sciences Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 84,525,843 | 84,073,162 | 79,912,907 | 94,865,111 |
| Revenue | 23,147,000 | 22,449,000 | 22,127,000 | 26,107,000 |
| EBITDA | 4,119,000 | 7,559,000 | 10,305,000 | 15,933,000 |
| Net Income | 1,268,000 | 5,386,000 | 5,455,000 | 4,628,000 |
| Total Assets | 60,878,000 | 61,627,000 | 63,675,000 | 70,283,000 |
| Total Debt | 29,290,000 | 24,593,000 | 27,322,000 | 33,542,000 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Gilead Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Gilead Sciences‘s full profile, request access.
Request a free trialGilead Sciences Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portf
Biotechnology
Foster City, CA
11,800
As of 2019
00.000
0&0
00000000
lit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
000000000000000
Basel, Switzerland
000000
As of 0000
000000000000
0000000
lor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
000000000000000
Boston, MA
0000
As of 0000
000000&0
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialGilead Sciences Competitors (62)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novartis | Corporation | Basel, Switzerland | 000000 | 000000000000 | ||
| 0000000 | Formerly VC-backed | Boston, MA | 0000 | 000000&0 | ||
| 00000 | Formerly PE-Backed | Thousand Oaks, CA | 00000 | 00.000 | 000000000000 | 00.000 |
| 000000 | Formerly VC-backed | Cambridge, MA | 0000 | 000.00 | 00000000000 | 000.00 |
| 00000 & 00. | Corporation | Kenilworth, NJ | 00000 | 00000000 |
Gilead Sciences Executive Team (49)
Gilead Sciences Board Members (23)
| Name | Representing | Role | Since |
|---|---|---|---|
| Anthony Welters JD | Self | Board Member | 000 0000 |
| Daniel O'Day | Gilead Sciences | Chief Executive Officer, Chairman of the Board & Director | 000 0000 |
| Harish Manwani | Self | Board Member | 000 0000 |
| Jacqueline Barton | Self | Board Member | 000 0000 |
| Javier Rodriguez | Self | Board Member | 000 0000 |
Gilead Sciences Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialGilead Sciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Gilead Sciences‘s full profile, request access.
Request a free trialGilead Sciences Investments & Acquisitions (47)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000000 | 23-Oct-2020 | 000000000000000000 | 0000 | Drug Discovery | 000000 0'000 |
| 000000 | 13-Oct-2020 | 00000 00000 00 | 0000 | Decision/Risk Analysis | 0000000 000000000 |
| 00000 000000000000 | 17-Aug-2020 | 00000 00000 00 | 0000 | Drug Discovery | |
| 000000 00000000000 | 21-Jul-2020 | 000000000000000000 | 00000 | Biotechnology | 000000 0'000 |
| Glympse Bio | 15-Jul-2020 | Early Stage VC | 000.00 | Diagnostic Equipment |
Gilead Sciences Subsidiaries (3)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Kite Pharma | Biotechnology | Santa Monica, CA | 2009 |
| 000000 | Pharmaceuticals | Westminster, CO | 0000 |
| 000000000000 | Drug Discovery | Morris Plains, NJ | 0000 |
Gilead Sciences Exits (5)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000000 00000000 | 01-Mar-2019 | 00000 00000 00 | 00000 | Completed |
|
| 0000000 000000 | 11-Dec-2017 | 00000 00000 00 | 000.00 | Completed |
|
| 0000000 0000000000 | 17-Mar-2014 | 00000 00000 00 | 0000 | Completed |
|
| 000000000 | 03-Dec-2004 | 00000 00000 00 | 000 | Completed |
|
| TriPharm Services | 16-Jan-2003 | Merger/Acquisition | 00000 | Completed |